RNA Clinical Trials Articles

  1. Capstan Therapeutics' Next Steps For In Vivo CAR Therapies 9/19/2022

    Capstan Therapeutics is a brand-new biotech company dedicated to developing and delivering precise in vivo cell engineering to patients. With $165 million in financing, Capstan Therapeutics aims to build on the foundational insights of leaders in mRNA and cell therapy from the University of Pennsylvania. Laura Shawver, Ph.D., leads the company as President and CEO, and on the heels of the biotech’s recent news, I caught up with her to learn more about the company’s plans for developing in vivo CAR therapies.

  2. Don't Get Uppity: Match mRNA Science To Your Capabilities — And Vice Versa 9/6/2022

    This article is part one of a four-part series unpacking four of my biggest takeaways from the mRNA Therapeutics Summit, which took place in Boston on July 27 & 28, 2022.

  3. The Promise Of Gene Silencing To Treat Not-So-Rare Diseases 9/2/2022

    In this last article in the series on siRNA, I examine its potential for treating not-so-rare and common diseases. Unlike rare diseases, which are often caused by pathological genetic mutations, common diseases may be associated with genetic variants that are not pathological. I look at cardiovascular disease and iron flux redux in particular.

  4. The Potential Of siRNA To Treat Rare Diseases 8/19/2022

    siRNA is a precision, targeted medicine with the potential to treat many diseases that currently lack effective therapeutic options. In this second article of my series on the subject, I take a closer look at siRNA’s potential for treating rare diseases. 

  5. The Promise Of Gene Silencing: A Primer On siRNA 8/5/2022

    Small interfering RNAs (siRNAs) are short sequences of RNA that interfere with gene expression, reducing or eliminating the expression of a disease-related protein by targeting its corresponding mRNA. siRNAs could treat a wide array of diseases. How does it differ from other therapeutic modalities such as gene therapy and gene editing?

  6. How Can We Move RNA Forward In Our Therapeutics Arsenal? 7/18/2022

    RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality. However, they have unique challenges. BioPhorum has dedicated a team to investigate these challenges and this Q&A shares their practical considerations for how to move this field forward.

  7. Expanding RNA-Based Immune Profiling To Immune State 4/27/2022

    A complete model of the tumor biology is showing promise to become a new standard for predicting patient response and helping more patients benefit from the power of immunotherapy. Expanding RNA-based immune profiling to immune state makes precision medicine more precise.

  8. mRNA Vaccines: Key Considerations For Development & Manufacturing 4/4/2022

    As we wind down National Immunization Awareness Month, this article looks at the complexities around developing and manufacturing mRNA vaccines and how you should address those complexities. Topics include delivery, process validation, long-term effectiveness, GMP, regulatory approval, and more. 

  9. The Current Landscape Of mRNA Vaccines In Clinical Research 3/17/2022

    With the Pfizer-BioNTech and Moderna products, mRNA vaccines made global headlines in 2021 in the fight against COVID-19. As we recognize National Immunization Awareness Month, this article shares how mRNA vaccines currently in clinical research and clinical trials may be soon used to fight HIV-1, herpes, cancer, and more.

  10. RNA's Delivery Challenges 3/16/2022

    Targeted delivery is a major hurdle for effective RNA Therapeutics, a hurdle that must be overcome to broaden the application of clinical translation of cell therapeutics. The mRNA-based therapeutic modality is new to emerging field of immuno-oncology, often referred to as immunotherapy.